Clinical trial · Interventional
Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
A Phase 2, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of TRM-1 (Fully Human Monoclonal Antibody To TRAIL-R1) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer
NCT00092924CI-TRIAL-00011553completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TRAIL-R1 mAb (TRM-1;HGS-ETR1) | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Primary Inclusion Criteria: * Relapsed or refractory histologically or cytologically confirmed Stage IIIB, IV, or recurrent NSCLC * Previously treated and failed to respond to standard therapy or progressed after standard therapy * 18 years of age or older Primary Exclusion Criteria: * Received a non-FDA approved investigational agent within the last 4 weeks. * Previous cancer therapies (chemotherapy, hormonal therapy, monoclonal antibodies or radiation therapy) within the last 3 weeks, 8 weeks for fully human or humanized monoclonal antibodies * Infection requiring antibiotics or hospitalization within the last 2 weeks * HIV, Hepatitis-B, Hepatitis-C * Pregnant or breast-feeding women * Major surgery within the last 4 weeks * History of other cancers within the past 5 years
References
Publications (0)
Data not yet available
No reference posted for this study.